Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and
therapeutic indications, today announced that the company will participate in the 2017 Wells Fargo Securities Healthcare Conference
in Boston, MA.
President and Chief Executive Officer, Dan Browne, is scheduled to participate in a fireside chat discussion on Wednesday,
September 6 at 3:35pm ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company
is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug
molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly
purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. The company
holds worldwide rights to RT002 injectable and RT001 topical and the pharmaceutical uses of its proprietary peptide technology
platform. More information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Investors:
Revance Therapeutics
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Burns McClellan
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170830005881/en/